Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more

Our tests

Additional advanced diagnostic tests

In addition to the CTC tests and Onconomics panel, we also offer a variety of tests that study the genetic makeup of cancer cells. 

Our tests help equip patients and their practitioners with information that can help guide the best treatment choices for each patient. These tests offer advanced diagnostic capabilities that can assess patients’ immune systems, identify chromosomal abnormalities, and prepare for the possibility of cancer metastasis.

Learn more about our advanced cancer diagnostic offerings below.

ChemoSNiP

ChemoSNiP is an innovative test that analyzes how a patient’s body responds to or metabolizes a specific drug. The test uses an advanced scientific technique called pharmacogenomics for this.

Pharmacogenomics is based on the principles of precision medicine, which aims to tailor medical treatment to each person or group of people. With pharmacogenomics, scientists look at how your DNA affects how your body responds to specific drugs.

How ChemoSNiP works

ChemoSNiP analyzes a blood sample to identify single nucleotide polymorphisms (SNPs). SNPs are variations in your DNA sequence that can affect whether you will respond to treatments with chemicals, drugs, and other agents.

The test examines how your body metabolizes drugs (pharmacokinetics) and how inherited variations in genes dictate drug response. The test explores the way these variations can be used to predict whether a patient will have a good response, bad response, or no response to the drug.

When used together with data from chemosensitivity testing, ChemoSNiP helps to narrow the selection to the most effective and least toxic therapeutic agent.

Therefore, ChemoSNiP analyzes your blood sample to assess which drugs will most effectively treat your cancer. Having this type of personalized information available even before your treatment begins can be crucial to the success of your cancer treatment journey.

The results provide a personalized analysis that your practitioner can use to provide the most effective combination of drugs and treatments available.

Price in Euros: € 725

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample ChemoSNiP results

Immune-Frame

RGCC’s Immune-Frame test is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for activating or suppressing a patient’s immune system.

How Immune-Frame works

The results of Immune-Frame can be used to analyze the status of a patient’s immune system and to provide ongoing information about their health status. The test can be used for establishing a baseline and for monitoring therapeutic response to cellular therapies.

Clinicians can use this information to advise on potential health risks a patient may face and how these can be minimized.

The Immune-Frame uses cell-specific markers and the production of cytokines to detect the type(s) of cells that are responsible for activating or repressing a patient's immune system.

The test provides crucial information to help plan a patient’s treatment and to determine which therapy is appropriate by detailing the following.

  • Presence and stimulation of DCs (dendritic cells)
  • Specific Humoral and Cellular Immunity
  • Non-specific Cellular Immunity
  • Immunosuppressive Mechanisms
  • Activation of T and B Memory cells for long-term immunity

Price in Euros: € 825

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample Immune-Frame results

Metastat

Metastat is an advanced test to accurately predict whether a secondary cancerous tumor is likely to develop and its potential location in your body. It can be a valuable tool for your specialist to personalize your cancer treatment.

For instance, it can accurately predict if secondary cancer may develop in the lungs, brain, liver, or bones.

How Metastat works

Metastat is suitable for all patients who have received a confirmed cancer diagnosis. Information from this test guides your specialist in selecting the best chemotherapeutic treatment for your body. 

The test studies the circulating tumor cells (CTC) of the primary tumor in your body. If your cancer has the probability of metastasizing, it tends to express specific genes and proteins according to the organ that is likely to metastasize. 

The Metastat test uses a cancer patient’s blood samples as input for analysis. It detects the level of specific marker genes and the level of proteins produced by these genes. These genetic markers coming from the cancerous tumor signal the ability for cancer recurrence. 

The results are then compared with the patient’s baseline data or control sample.

Price in Euros: € 825

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample Metastat results

aCGH

The array comparative genomic hybridization (aCGH) test checks for chromosomal abnormalities and other genetic disorders in patients. The aCGH test can identify imbalances in an entire genome with higher resolution than traditional microscopic methods.

How aCGH works

The test is a powerful follow-up tool for early detection of cancer recurrence. This follow-up test can help to control the risk of relapse and monitor the patient’s status during and after treatment.

The test is beneficial when the primary origin of the cancer tumor is unknown. In such a case, the aCGH test helps identify chromosomal abnormalities to help detect the location of the cancer.

During the test, our scientists use a technique called array comparative genomic hybridization, or aCGH, to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumor. 

aCGH helps clinicians understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.

Price in Euros: € 725

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample aCGH results

CAMBISeq®

CAMBISeq® stands for Cancer Analysis Mutational Burden Instability Sequencing. It provides next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into one’s cancer.

How CAMBISeq® works

CAMBISeq® is used to identify variants in up to 500 genes. We use these genes as biomarkers to assess a patient’s sensitivity to immunotherapy and other therapies. The results can predict how well the patient will respond to different types of therapy.

The test is sensitive enough to detect even very rare gene mutations. CAMBISeq® is typically used in cases where first-line therapies have been exhausted. It helps determine if the patient may respond well to immunotherapy, targeted therapies, or clinical trials as additional treatment options.

CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. Clinicians can use the test to identify the best and most effective combinations of cancer treatments.

Price in Euros: € 3100

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample CAMBISeq® results

InVyomma Plus

The InVyomma Plus test is a cutting-edge medical test that focuses on profiling a patient’s gut microbiome. This is achieved by analyzing short-chain fatty acids and their associations with cancer.

How InVyomma Plus works

Research shows that gut microbiomes can directly contribute to cancer development by producing toxic metabolites or carcinogenic substances. Gut microbiomes can also indirectly promote cancer by inducing inflammation and immunosuppression and affecting the efficacy and toxicity of cancer therapies.

This test examines the composition and characteristics of the gut microbiome, which is the collection of microorganisms living in the digestive tract. InVyomma Plus specifically looks at short-chain fatty acids to understand their link to the development of various cancer types.

This test provides valuable information to our clinicians and offers insights that can guide personalized treatment strategies. This can potentially improve patient outcomes by considering the gut microbiome's role in cancer development and therapy.

The InVyomma Plus test is performed on stool samples from the patient.

Price in Euros: € 790

Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.

View sample InVyomma Plus results

Access our advanced diagnostic tests

Our scientists use world-leading technology, equipment, and innovative techniques to develop a range of cancer screening and monitoring tests. Our tests help cancer patients and their healthcare professionals get a comprehensive but personalized view of each patient’s genetics, physiology, and immune profiles.

We believe this level of detail is crucial in developing an individualized care plan for every patient struggling with cancer. We aim to provide a unique insight into every patient’s cancer biology to empower them about what treatment modalities are ideal for bringing them success in their cancer journey!

Reach out to us to start your journey to empowering information for your cancer treatment today by contacting us online.

Follow Us
Accreditations
IAS Accreditation
Testing Laboratory
View TL-836 Certificate
EN ISO 22000: 2018
No: 20101200002689
View Certificate
IAS Accreditation
Medical Laboratory
View ML-103 Certificate
ISO 22000: 2018
No: 20101200002689
View Certificate
ISO 45001: 2018
No: 20152220006395
View CertificatePolicy
ISO 22716: 2007
No: 20019220006394
View Certificate
CLIA ID Number
99D2283882
View Certificate
College of American Pathologists 
Certificate of Accreditation
CAP#: 9239089 
CLIA#: 99D2283882 
View Certificate
Certificate of GMP Compliance
No. 512863-102689104
View Certificate
Accreditation Certificate of Foreign Cell Processor - Japanese Government
View Certificate
EOF GMP COSMETICS – SUPPLEMENTS
View Certificate
Accreditations
IAS Accreditation
Testing Laboratory
View TL-836 Certificate
EN ISO 22000: 2018
No: 20101200002689
View Certificate
IAS Accreditation
Medical Laboratory
View ML-103 Certificate
ISO 22000: 2018
No: 20101200002689
View Certificate
ISO 45001: 2018
No: 20152220006395
View CertificatePolicy
ISO 22716: 2007
No: 20019220006394
View Certificate
CLIA ID Number
99D2283882
View Certificate
College of American Pathologists 
Certificate of Accreditation
CAP#: 9239089 
CLIA#: 99D2283882 
View Certificate
Certificate of GMP Compliance
No. 512863-102689104
View Certificate
Accreditation Certificate of Foreign Cell Processor - Japanese Government
View Certificate
EOF GMP COSMETICS – SUPPLEMENTS
View Certificate
Call
Text
Email
Map